TET1 reprograms the epithelial ovarian cancer epigenome and reveals casein kinase 2α as a therapeutic target

Area of Science:

• Epigenetics
• Cancer Biology
• Ovarian Carcinogenesis

Background:

• DNA demethylation plays a role in cancer, but its significance in ovarian cancer is unclear.
• Ten-eleven translocation methylcytosine dioxygenase-1 (TET1) is involved in active DNA demethylation.
• Limited understanding of TET1's role in epithelial ovarian carcinoma (EOC) and its precursor lesions.

Purpose of the Study:

• To investigate the role of TET1 in EOC development and progression.
• To explore the clinical significance of TET1 expression in EOC patients.
• To identify potential therapeutic targets based on TET1's function.

Main Methods:

• Analysis of TET1 expression in EOC tissues and precursor lesions (STIC).
• Correlation of TET1 levels with patient survival, clinicopathological features, and TP53 mutations.
• In vitro and in vivo studies to assess the functional impact of TET1 on cancer stemness, tumorigenicity, and response to therapy.

Main Results:

• TET1 expression correlates with poor survival, increased migration, stemness, and tumorigenicity in advanced EOC.
• TET1 is highly expressed in STIC and inversely correlated with TP53 mutations.
• TET1 demethylates the epigenome, activating oncogenic pathways including an immunomodulation network centered on CK2α.
• Combined high TET1 and CK2α expression indicates the worst prognosis.
• TET1-expressing EOCs show sensitivity to a CK2 inhibitor (CX4945).

Conclusions:

• TET1 acts as an oncogene in EOC, contributing to epigenetic reprogramming and poor prognosis.
• TET1 may play a role in early ovarian carcinogenesis.
• CK2α is a promising therapeutic target in EOC.
• The CK2 inhibitor CX4945 warrants clinical trials for precision medicine in EOC.